Old Web
English
Sign In
Acemap
>
authorDetail
>
Amy Andre
Amy Andre
Johns Hopkins University
Medicine
Pharmacokinetics
Diabetes mellitus
Atrasentan
Urology
4
Papers
158
Citations
0.00
KQI
Citation Trend
Filter By
Interval:
1900~2024
1900
2024
Author
Papers (4)
Sort By
Default
Most Recent
Most Early
Most Citation
No data
Journal
Conference
Others
Atrasentan, a n E ndothelin-Recep tor A ntagonist f or Refractory A denocarcinomas: S afety a nd P harmacokinetics
2013
M. A. Carducci
Joel B. Nelson
M. Kathy Bowling
Theresa Rogers
Mario A. Eisenberger
Victoria J. Sinibaldi
Ross C. Donehower
Terri Leahy
Robert A. Carr
Jeffrey D. Isaacson
Todd J. Janus
Amy Andre
Balakrishna Hosmane
Robert J. Padley
Show All
Source
Cite
Save
Citations (0)
The effect of hepatic insufficiency on the safety and pharmacokinetics of paricalcitol (Zemplar
2006
Nephron Clinical Practice
Robert A. Carr
Amy Andre
Ping Chen
Brian A. Grabowski
Min S. Chang
Charles S. Locke
Laura A. Williams
Mario Chojkier
Show All
Source
Cite
Save
Citations (2)
Atrasentan (ABT-627, ATN) pharmacokinetics (PK) and endothelin-1 (ET-1) pharmacodynamics (PD) in a phase 2 study of patients with asymptomatic hormone-refractory prostate cancer (HRPC)
2004
Journal of Clinical Oncology
Robert A. Carr
Balakrishna Hosmane
Amy Andre
T. Yanke
K Hamel
A. Allen
Show All
Source
Cite
Save
Citations (3)
Atrasentan, an Endothelin-Receptor Antagonist for Refractory Adenocarcinomas: Safety and Pharmacokinetics
2002
Journal of Clinical Oncology
Michael A. Carducci
Joel B. Nelson
M. Kathy Bowling
Theresa Rogers
Mario A. Eisenberger
Victoria J. Sinibaldi
Ross C. Donehower
Terri Leahy
Robert A. Carr
Jeffrey D. Isaacson
Todd J. Janus
Amy Andre
Balakrishna S. Hosmane
Robert J. Padley
Show All
Source
Cite
Save
Citations (153)
1